IDEXX Laboratories (IDXX) vs Labcorp (LH)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 10, 2026.
Summary
Labcorp (LH) has outperformed IDEXX Laboratories (IDXX) over the past year, gaining 12.4% versus a loss of 17.6%. Over five years, LH leads with a +33.8% price change compared with -18.4% for IDXX. IDEXX Laboratories is the larger company by market cap ($40.81 billion vs $25.32 billion), about 1.6 times the size.
On valuation, Labcorp trades at a lower forward P/E (15.8x vs 30.9x for IDEXX Laboratories). Labcorp pays a dividend yielding 0.92%, while IDEXX Laboratories does not currently pay one. IDEXX Laboratories converts more of its revenue into profit, with a net margin of 24.6% versus 6.3%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | IDXX | LH |
|---|---|---|
| Share price | $518.00 | $312.15 |
| Market cap | $40.81B | $25.32B |
| 1-day change | +0.95% | -0.65% |
| YTD return | -23.43% | +24.42% |
| 1-year return | -17.61% | +12.37% |
| 5-year return | -18.44% | +33.78% |
| P/E ratio (TTM) | 36.40 | 25.99 |
| Forward P/E | 30.95 | 15.78 |
| EPS (TTM) | $14.23 | $12.01 |
| Dividend yield | 0.00% | 0.92% |
| Annual dividend | $0.00 | $2.88 |
| Revenue (latest FY) | $4.30B | $13.95B |
| Revenue growth (YoY) | +10.42% | +7.25% |
| Net income (latest FY) | $1.06B | $876.50M |
| Gross margin | 61.80% | 28.76% |
| Operating margin | 31.60% | 9.92% |
| Net margin | 24.62% | 6.28% |
| 52-week high | $769.98 | $341.80 |
| 52-week low | $500.61 | $244.52 |
| Distance from 52-week high | -32.73% | -8.67% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +35.39% | +10.26% |
| Average volume | 553.95K | 747.49K |
| Shares outstanding | 78.78M | 81.10M |
| Employees | 11,000 | 71,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: In Vitro & In Vivo Diagnostic Substances | Medical Specialities |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- LH has outperformed IDXX by 30.0 percentage points over the past year.
- IDEXX Laboratories trades at a higher earnings multiple (36.4x vs 26.0x trailing P/E).
- IDEXX Laboratories is more profitable, keeping 24.6 cents of every revenue dollar as net income versus 6.3 cents for Labcorp.
About IDEXX Laboratories
IDXX stock →IDEXX Laboratories, Inc. develops, manufactures, and distributes products for the companion animal veterinary, livestock and poultry, dairy, and water testing industries in the United States and internationally.
Health Care · Biotechnology: In Vitro & In Vivo Diagnostic Substances · 11,000 employees
About Labcorp
LH stock →Labcorp Holdings Inc. provides laboratory services.
Health Care · Medical Specialities · 71,000 employees
IDXX vs LH FAQ
Which is bigger, IDEXX Laboratories or Labcorp?
IDEXX Laboratories (IDXX) is larger, with a market capitalization of $40.81B compared with $25.32B for Labcorp (LH).
Which stock has performed better over the past year, IDXX or LH?
LH returned +12.37% over the past 12 months, compared with -17.61% for IDXX (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, IDXX or LH?
LH has the lower trailing P/E at 26.0, versus 36.4 for IDXX. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, IDEXX Laboratories or Labcorp?
Labcorp pays a dividend yielding 0.92%, while IDEXX Laboratories does not currently pay a regular dividend.
Are IDEXX Laboratories and Labcorp in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: In Vitro & In Vivo Diagnostic Substances for IDEXX Laboratories and Medical Specialities for Labcorp.